Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.（TRDA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TRDA · 截至 2026年6月8日
活动摘要
买入笔数
17
P-Purchase only
卖出笔数
19
近12个月
买卖比
0.89
Buy/Sell (by trades)
整体情绪
Entrada Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
TRDA 季度内部人买卖趋势
TRDA 内幕交易卖出 · TRDA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · TRDA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TRDA 高管卖出股份 · TRDA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 20, 2026 | Zeiher Bernhardt G Director | Purchase | 5,000 | $29K | Form 4 |
| May 4, 2026 | Sethuraman Natarajan President, Research & Develop. | Sale | 25,907 | $399K | Form 4 |
| May 4, 2026 | Dowden Nathan J President & COO | Option | 15,000 | $26K | Form 4 |
| May 4, 2026 | Dowden Nathan J President & COO | Sale | 15,000 | $230K | Form 4 |
| Apr 1, 2026 | WENTWORTH KORY JAMES CFO | Sale | 2,500 | $32K | Form 4 |
| Mar 9, 2026 | Dowden Nathan J President & COO | Sale | 3,116 | $41K | Form 4 |
| Mar 10, 2026 | Dowden Nathan J President & COO | Sale | 11,894 | $155K | Form 4 |
| Mar 9, 2026 | WENTWORTH KORY JAMES CFO | Sale | 5,089 | $66K | Form 4 |
| Mar 10, 2026 | WENTWORTH KORY JAMES CFO | Sale | 11,388 | $148K | Form 4 |
| Mar 4, 2026 | WENTWORTH KORY JAMES CFO | Sale | 7,988 | $98K | Form 4 |
| Mar 1, 2026 | Doshi Dipal CEO · Director | Award | 139,400 | — | Form 4 |
| Mar 2, 2026 | Doshi Dipal CEO · Director | Other | 9,869 | $115K | Form 4 |
| Mar 3, 2026 | Doshi Dipal CEO · Director | Other | 19,181 | $225K | Form 4 |
| Mar 1, 2026 | WENTWORTH KORY JAMES CFO | Award | 44,600 | — | Form 4 |
| Mar 2, 2026 | WENTWORTH KORY JAMES CFO | Other | 2,939 | $34K | Form 4 |
| Mar 3, 2026 | WENTWORTH KORY JAMES CFO | Other | 5,712 | $67K | Form 4 |
| Mar 1, 2026 | Dowden Nathan J President & COO | Award | 55,800 | — | Form 4 |
| Mar 2, 2026 | Dowden Nathan J President & COO | Other | 7,223 | $84K | Form 4 |
| Mar 3, 2026 | Dowden Nathan J President & COO | Other | 14,038 | $165K | Form 4 |
| Mar 1, 2026 | Sethuraman Natarajan President, Research & Develop. | Award | 55,800 | — | Form 4 |
| Mar 2, 2026 | Sethuraman Natarajan President, Research & Develop. | Other | 3,898 | $45K | Form 4 |
| Mar 3, 2026 | Sethuraman Natarajan President, Research & Develop. | Other | 7,577 | $89K | Form 4 |
| Nov 21, 2025 | WENTWORTH KORY JAMES CFO | Sale | 8,910 | $89K | Form 4 |
| Nov 20, 2025 | BAKER BROS. ADVISORS LP 10 percent owner | Purchase | 13,082 | $119K | Form 4 |
| Nov 20, 2025 | BAKER BROS. ADVISORS LP 10 percent owner | Purchase | 13,386 | $121K | Form 4 |
Sethuraman Natarajan
President, Research & Develop.
日期
May 4
股数
25,907
均价
$15.39
总金额
$399K
Sethuraman Natarajan
President, Research & Develop.
日期
Mar 2
股数
3,898
均价
$11.66
总金额
$45K
Sethuraman Natarajan
President, Research & Develop.
日期
Mar 3
股数
7,577
均价
$11.76
总金额
$89K
BAKER BROS. ADVISORS LP
10 percent owner
日期
Nov 20
股数
13,082
均价
$9.07
总金额
$119K
BAKER BROS. ADVISORS LP
10 percent owner
日期
Nov 20
股数
13,386
均价
$9.07
总金额
$121K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TRDA 内幕交易
TRDA 内幕交易
Entrada Therapeutics, Inc.（TRDA）内幕交易数据来源于公司内部人（包括BAKER BROS. ADVISORS LP (10 percent owner), WENTWORTH KORY JAMES (CFO), PARMAR KUSH (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。TRDA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Entrada Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TRDA 内幕交易 · 5个问题Entrada Therapeutics, Inc.（TRDA）的内部人包括高管和董事，如BAKER BROS. ADVISORS LP (10 percent owner), WENTWORTH KORY JAMES (CFO), PARMAR KUSH (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026